Long-term life expectancy for children with ependymoma and medulloblastoma
Jonathan E. Frandsen MD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorAaron Wagner MD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorRobert J. Bollo MD, MS
Department of Neurosurgery, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorDennis C. Shrieve MD, PhD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorCorresponding Author
Matthew M. Poppe MD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Correspondence to: Matthew Poppe, University of Utah, Huntsman Cancer Hospital, 1950 Circle of Hope, Room 1570, Salt Lake City, UT 84112.
E-mail: [email protected]
Search for more papers by this authorJonathan E. Frandsen MD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorAaron Wagner MD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorRobert J. Bollo MD, MS
Department of Neurosurgery, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorDennis C. Shrieve MD, PhD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Search for more papers by this authorCorresponding Author
Matthew M. Poppe MD
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, Utah
Correspondence to: Matthew Poppe, University of Utah, Huntsman Cancer Hospital, 1950 Circle of Hope, Room 1570, Salt Lake City, UT 84112.
E-mail: [email protected]
Search for more papers by this authorAbstract
Objectives
There is a paucity of long-term follow-up data for children with intracranial ependymoma (IE) and medulloblastoma (MB). What happens to these children 20, 30, or 40 years after diagnosis? Do they have potential for a normal lifespan? The purpose of this study was to ascertain the long-term survival potential in children with MB or IE who have survived 5 years from diagnosis.
Methods
A retrospective analysis was conducted using the SEER Program. Children (ages 0–19 years) from 1973 to 2011 with a diagnosis of MB or IE were identified. A cohort was created of potentially cured patients who survived 5 years from diagnosis. Cox proportional hazards models and Kaplan–Meier estimates were utilized to analyze long-term survival.
Results
We identified 876 patients with MB and 474 patients with IE who were alive 5 years from diagnosis. Patients with MB had a 30-year overall survival (OS) and cancer-specific survival (CSS) of 70.2% and 80.1%, respectively. Patients with IE had a 30-year OS and CSS of 57.3% and 68.8%, respectively. When comparing MB with IE, MB had improved CSS (P = 0.04) and trended toward increased OS (P = 0.10).
Conclusions
A significant number of deaths due to disease occur for several decades after treatment for both IE and MB. Despite this, the potential for long-term survival exists in 5-year survivors of both histologies. If alive at 5 years from diagnosis, patients with MB tend to have a lower risk of death from disease compared to those with IE. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.
REFERENCES
- 1 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, KA Cronin. SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2011/. Based on November 2013 SEER data submission, posted to the SEER web site, January 11, 2014.
- 2 Shu HK, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN, Fisher MJ. Childhood intracranial ependymoma: Twenty-year experience from a single institution. Cancer 2007; 110: 432–441.
- 3 Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 946–958.
- 4 Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study. Lancet Oncol 2009; 10: 258–266.
- 5 Gajjar A, Chintagumpala M, Ashley D. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 797.
- 6 Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, Chen Z, Burger P, Barnes P, Kun L. High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 2013; 31: 2936–2941.
- 7 Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: Results of Children's Oncology Group trial A 9961. Neuro Oncol 2013; 15: 97–103.
- 8 Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS, Silva M, Odame I, Mpofu C, Strother D, Wilson B, Samson Y, Bouffet E. Canadian Pediatric Brain Tumor Consortium. Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management: A Canadian Pediatric Brain Tumor Consortium Study. Cancer 2005; 103: 1874–1880.
- 9 Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study. Lancet Oncol 2009; 10: 258–266.
- 10 Halperin EC, Constine LS, Tarbell NJ, Kun LE. Pediatric radiation oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2011. p. 53–72.
- 11 Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study. Lancet Oncol 2009; 10: 258–266.
- 12 van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, Sainte-Rose C, Zerah M, Thorne J, Renier D. Ependymoma in childhood: Prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 2002; 97: 827–835.
- 13 Shu HK, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN, Fisher MJ. Childhood intracranial ependymoma: Twenty-year experience from a single institution. Cancer 2007; 110: 432–441.
- 14 Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, Luchtman-Jones L, Rich KM, Grigsby PW, Lockett MA, Wahab SH, Simpson JR. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61: 387–391.
- 15 Robertson PL, Zeltzer PM, Boyett JM, Rorke LB, Allen JC, Geyer JR, Stanley P, Li H, Albright AL, McGuire-Cullen P, Finlay JL, Stevens KR, Jr, Milstein JM, Packer RJ, Wisoff J. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: A report of the Children's Cancer Group. J Neurosurg 1998; 88: 695–703.
- 16 Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: Aanalysis of prognostic factors and patterns of failure. J Neurooncol 2002; 56: 87–94.
- 17 Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M. Intracranial ependymomas of childhood: Long-term outcome and prognostic factors. Neurosurgery 1995; 37: 655–666.
- 18 Rousseau P, Habrand JL, Sarrazin D, Kalifa C, Terrier-Lacombe MJ, Rekacewicz C, Rey A. Treatment of intracranial ependymomas of children: Review of a 15-year experience. Int J Radiat Oncol Biol Phys 1994; 28: 381–386.
- 19 Massimino M, Giangaspero F, Garrè ML, Genitori L, Perilongo G, Collini P, Riva D, Valentini L, Scarzello G, Poggi G, Spreafico F, Peretta P, Mascarin M, Modena P, Sozzi G, Bedini N, Biassoni V, Urgesi A, Balestrini MR, Finocchiaro G, Sandri A, Gandola L. AIEOP Neuro-Oncology Group. Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting “at once” adjuvant treatment. Int J Radiat Oncol Biol Phys 2006; 65: 1440–1445.
- 20 van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, Sainte-Rose C, Zerah M, Thorne J, Renier D. Ependymoma in childhood: Prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 2002; 97: 827–835.
- 21 Merchant TE, Jenkins JJ, Burger PC, Sanford RA, Sherwood SH, Jones-Wallace D, Heideman RL, Thompson SJ, Helton KJ, Kun LE. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys 2002; 53: 52–57.
- 22 Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC, Edan C, Chastagner P, Kalifa C, French Society of Pediatric Oncology. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001; 19: 1288–1296.
- 23 Hukin J, Epstein F, Lefton D, Allen J. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998; 29: 40–45.
- 24 Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study. Lancet Oncol 2009; 10: 258–266.
- 25
Perilongo G,
Massimino M,
Sotti G,
Belfontali T,
Masiero L,
Rigobello L,
Garrè L,
Carli M,
Lombardi F,
Solero C,
Sainati L,
Canale V,
del Prever AB,
Giangaspero F,
Andreussi L,
Mazza C,
Madon E.
Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group.
Med Pediatr Oncol
1997;
29: 79–85.
10.1002/(SICI)1096-911X(199708)29:2<79::AID-MPO3>3.0.CO;2-O CAS PubMed Web of Science® Google Scholar
- 26 Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M. Intracranial ependymomas of childhood: Long-term outcome and prognostic factors. Neurosurgery 1995; 37: 655–666.
- 27 Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC, Edan C, Chastagner P, Kalifa C. French Society of Pediatric Oncology. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001; 19: 1288–1296.
- 28 Merchant TE, Jenkins JJ, Burger PC, Sanford RA, Sherwood SH, Jones-Wallace D, Heideman RL, Thompson SJ, Helton KJ, Kun LE. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys 2002; 53: 52–57.
- 29 McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: A SEER study. Pediatr Blood Cancer 2009; 52: 65–69.
- 30 Mack SC, Taylor MD. The genetic and epigenetic basis of ependymoma. Childs Nerv Syst 2009; 25: 1195–1201.
- 31 Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board J, Macdonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8: 323–335.
- 32 Kilday JP, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B, Grundy R. Pediatric ependymoma: Biological perspectives. Mol Cancer Res 2009; 7: 765–786.
- 33 Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C. Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer 2007; 6: 47.
- 34 Janss AJ, Michalski J, ACNS 0331. A study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: A phase III double randomized trial. https://www.childrensoncologygroup.org/index.php/acns0331 (Accessed December 23, 2014).
- 35 Packer R, Olson J. ACNS 0332. Efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients. A Groupwide Phase III Study. https://www.childrensoncologygroup.org/index.php/acns0332 (Accessed December 23, 2014).
- 36 Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: A report from the Children's Cancer Group. Neurosurgery 1996; 38: 265–271.
- 37 Gajjar A, Sanford RA, Bhargava R, Heideman R, Walter A, Li Y, Langston JW, Jenkins JJ, Muhlbauer M, Boyett J, Kun LE. Medulloblastoma with brain stem involvement: The impact of gross total resection on outcome. Pediatr Neurosurg 1996; 25: 182–187.
- 38 Cutler EC, Sosman MC, Vaughan WW. Place of radiation in treatment of cerebellar medulloblastoma: Report of 20 cases. Am J Roentgenol Radium Ther Nucl Med 1936; 35: 429–453.
- 39 Bloom HJG, Gless J, Bell J. The treatment and prognosis of medulloblastoma in children. AJR Am J Roentgenol 1969; 105: 43–62.
- 40 Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17: 832–845.
- 41 Kellie SJ. Chemotherapy of central nervous system tumours in infants. Childs Nerv Syst 1999; 15: 592–612.
- 42 Helton KJ, Fouladi M, Boop FA, Perry A, Dalton J, Kun L, Fuller C. Medullomyoblastoma: A radiographic and clinicopathologic analysis of six cases and review of the literature. Cancer 2004; 101: 1445–1454.
- 43 Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park TS, Levy BK, Perry A. Large cell/anaplastic medulloblastomas and medullomyoblastomas: Clinicopathological and genetic features. J Neurosurg 2001; 95: 82–88.
- 44 Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, Burnelli R, Burger PC, Garrè ML. Medulloblastoma with extensive nodularity: A variant with favorable prognosis. J Neurosurg 1999; 91: 971–977.
- 45 Mell LK, Carmona R, Gulaya S, Lu T, Wu J, Saenz CC, Vaida F. Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: A population-based study. J Natl Cancer Inst 2013; 105: 1656–1666.
- 46 Lund JL, Harlan LC, Yabroff KR, Warren JL. Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease. Cancer Invest 2010; 28: 758–764.
- 47 Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2008; 70: 782–787.
